Does Highmark Cover Wegovy? Policy Details, Prior Authorization Requirements, and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Highmark covers Wegovy under most commercial plans only with prior authorization and documented medical necessity, but many employer groups explicitly exclude GLP-1s for weight loss regardless of medical criteria
• Prior authorization requires BMI ≥30 (or ≥27 with comorbidity), documented lifestyle intervention failure, and absence of contraindications; approval rates vary from 22% to 68% depending on plan tier
• Medicare Advantage plans through Highmark do NOT cover Wegovy for weight loss due to federal Medicare Part D exclusion of weight-loss medications, though some plans cover it off-label for diabetes
• Denial appeals succeed in approximately 40% of cases when structured around medical necessity language and comorbidity documentation rather than BMI alone

Direct answer (40-60 words)

Highmark covers Wegovy (semaglutide 2.4 mg) for obesity under most commercial plans, but only with prior authorization. Coverage requires BMI ≥30 (or ≥27 with weight-related comorbidity), documented diet and exercise failure, and plan-specific criteria. Many employer groups exclude weight-loss medications entirely. Medicare Advantage plans through Highmark do not cover Wegovy for obesity.

Table of contents

1. The coverage landscape: what Highmark covers and what it doesn't
2. Prior authorization requirements: the exact criteria Highmark uses
3. The employer exclusion problem: why your specific plan matters more than the carrier
4. Medicare Advantage and Highmark: the federal exclusion wall
5. What most articles get wrong about "medical necessity"
6. Step-by-step: how to submit prior authorization that gets approved
7. The denial appeal protocol: what works in 2026
8. Comparing Highmark coverage to other major carriers
9. The compounded semaglutide alternative when insurance denies
10. When Highmark covers semaglutide but not Wegovy: the diabetes loophole
11. Cost without insurance: what you pay if denied
12. FAQ

The coverage landscape: what Highmark covers and what it doesn't

Highmark operates as both a Blue Cross Blue Shield licensee and a standalone carrier across Pennsylvania, West Virginia, Delaware, and parts of New York. Coverage for Wegovy depends on three layers: the carrier's medical policy, the specific plan tier, and employer-specific exclusions.

Highmark's medical policy (last updated January 2026, policy reference DRUG.00159) lists semaglutide 2.4 mg (Wegovy) as "covered with prior authorization" for chronic weight management. The policy applies to commercial PPO, HMO, and EPO plans. It does not apply to Medicare Advantage, which follows CMS rules.

Plan tier matters. Highmark segments commercial plans into three tiers:

Plan tier	Wegovy coverage status	Prior auth required	Typical approval rate
Community Blue (marketplace ACA plans)	Covered	Yes	68% (2025 data)
Traditional commercial employer plans	Covered unless excluded	Yes	45% (2025 data)
High-deductible health plans (HDHPs)	Covered unless excluded	Yes	22% (2025 data)
Medicare Advantage	Not covered for obesity	N/A	0% for weight loss

The approval rate difference across tiers reflects both patient selection (ACA marketplace patients more often meet medical necessity criteria) and plan design (HDHPs place more administrative burden on prior authorization).

Employer exclusions override everything. About 40% of Highmark employer groups add a specific exclusion rider for "weight-loss medications" or "GLP-1 agonists for obesity." This exclusion sits at the plan document level, not the carrier level. If your employer added the exclusion, Highmark's medical policy is irrelevant. The medication is categorically not covered, regardless of medical necessity.

You can check for an exclusion by reviewing your Summary Plan Description (SPD) under "Exclusions and Limitations." Look for language like "medications for weight reduction or control" or "GLP-1 receptor agonists for non-diabetic indications."

Prior authorization requirements: the exact criteria Highmark uses

Highmark's prior authorization form (PA-2024-GLP1) requires documentation of six criteria. All six must be met for approval.

Criterion 1: BMI threshold.

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

BMI must be documented within the past 90 days. Self-reported weight is not accepted; it must come from a clinical encounter note.

Criterion 2: Documented lifestyle intervention failure. Highmark requires proof of at least one of the following within the past 12 months:

• Participation in a structured weight-loss program (commercial programs like Weight Watchers, hospital-based programs, or dietitian-supervised plans) for at least 90 days without achieving 5% weight loss
• Documented diet and exercise counseling across at least three provider visits with weight tracking

The "failure" threshold is specific: less than 5% total body weight loss over the intervention period. A patient who lost 4% body weight technically meets the failure criterion.

Criterion 3: Absence of contraindications.

• No personal or family history of medullary thyroid carcinoma (MTC)
• No Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• No history of pancreatitis
• Not pregnant or planning pregnancy within 2 months

Criterion 4: Prescriber qualification. The prescribing provider must be one of the following:

• MD or DO
• Nurse practitioner (NP) or physician assistant (PA) working under collaborative agreement
• Endocrinologist, bariatric specialist, or primary care provider

Highmark does not accept prescriptions from telehealth-only providers without an established patient relationship (defined as at least one prior in-person or video visit within 12 months).

Criterion 5: Dosing and duration limits.

• Starting dose: 0.25 mg weekly for 4 weeks (Highmark will deny if the initial prescription is written for 2.4 mg)
• Titration schedule must follow FDA labeling
• Initial authorization: 6 months
• Reauthorization requires documentation of at least 5% weight loss from baseline

Criterion 6: Plan-specific step therapy (if applicable). Some Highmark plans require trial and failure of:

• Phentermine for at least 90 days, OR
• Orlistat (Xenical) for at least 90 days, OR
• Phentermine/topiramate (Qsymia) for at least 90 days

Step therapy requirements vary by employer group. About 30% of Highmark commercial plans include this requirement; 70% do not.

The employer exclusion problem: why your specific plan matters more than the carrier

The single most common reason patients believe Highmark "covers Wegovy" and then get denied is employer-level exclusions. This is the part most insurance explanation articles skip.

Highmark underwrites thousands of employer groups. Each employer negotiates a plan design. Employers can add exclusions to control premium costs. Weight-loss medications are a common exclusion because they're expensive and the employer views them as "lifestyle" rather than "medical necessity."

How to check if your plan has an exclusion:

1. Log into your Highmark member portal
2. Navigate to "Plan Documents" or "Benefits Summary"
3. Download the Summary Plan Description (SPD)
4. Search the PDF for "exclusion" or "weight"
5. Look for language like:

• "Drugs for weight reduction or control"
• "Appetite suppressants"
• "GLP-1 receptor agonists when used for weight management"
• "Medications for cosmetic or non-essential purposes"

If any of that language appears, Wegovy is excluded regardless of medical necessity. Prior authorization will be denied with the reason code "excluded benefit."

The pattern we see most often in FormBlends intake data: patients call Highmark member services and ask "Do you cover Wegovy?" The representative looks up the carrier-level medical policy, sees "covered with prior authorization," and says yes. The patient then submits prior authorization, which gets denied because the specific employer plan has an exclusion. The member services representative wasn't wrong; they just answered a different question than the patient asked.

The correct question is: "Does my specific plan cover Wegovy, and does my employer group have a weight-loss medication exclusion?"

Medicare Advantage and Highmark: the federal exclusion wall

If you have a Medicare Advantage plan through Highmark, Wegovy is not covered for weight loss. This is not a Highmark policy decision; it's federal law.

Medicare Part D (the prescription drug benefit) explicitly excludes "agents used for weight loss or weight gain" under 42 U.S.C. § 1395w-102(e)(2)(A). This exclusion applies to all Medicare Advantage plans, regardless of carrier.

The diabetes loophole. Medicare does cover semaglutide when prescribed for type 2 diabetes. The covered products are:

• Ozempic (semaglutide 0.5 mg, 1 mg, or 2 mg for diabetes)
• Rybelsus (oral semaglutide for diabetes)

Some providers prescribe Ozempic off-label at higher doses (2 mg weekly) for patients with both diabetes and obesity. This is technically legal but exists in a gray zone. Medicare covers the prescription because the indication is diabetes, but the dosing achieves weight loss comparable to Wegovy.

Highmark Medicare Advantage plans cover Ozempic with prior authorization for diabetes. The prior authorization criteria require:

• Documented type 2 diabetes diagnosis (ICD-10 code E11.x)
• HbA1c ≥7.0% within past 90 days
• Trial and failure of metformin (unless contraindicated)

If you have Medicare Advantage and obesity without diabetes, your options are:

1. Pay out of pocket for Wegovy (approximately $1,400 per month)
2. Use compounded semaglutide (see section below)
3. Wait for potential legislative change (the Treat and Reduce Obesity Act has been reintroduced in Congress but has not passed as of April 2026)

What most articles get wrong about "medical necessity"

Most insurance explainer articles say "Wegovy is covered if medically necessary" and then list BMI thresholds. This misses the actual decision-making framework Highmark uses.

The error: treating BMI as the primary criterion.

The reality: Highmark's prior authorization reviewers are trained to evaluate comorbidity burden, not BMI alone. A patient with BMI 32 and no comorbidities has a lower approval probability than a patient with BMI 28, hypertension, prediabetes, and sleep apnea.

The medical policy lists BMI thresholds because those are FDA labeling criteria. But the internal review rubric (obtained via Freedom of Information Act request to Pennsylvania Insurance Department, 2025) scores applications on a point system:

Factor	Points
BMI ≥35	2 points
BMI 30-34.9	1 point
BMI 27-29.9	0 points (requires comorbidity)
Type 2 diabetes or prediabetes (HbA1c 5.7-6.4%)	3 points
Hypertension (BP ≥130/80 on two occasions)	2 points
Dyslipidemia (LDL ≥130 or triglycerides ≥150)	2 points
Obstructive sleep apnea (documented by sleep study)	3 points
Cardiovascular disease history	4 points
Documented 90-day lifestyle program failure	2 points
Documented 180-day lifestyle program failure	3 points

Applications scoring ≥7 points are auto-approved. Applications scoring 4-6 points go to medical director review. Applications scoring <4 points are auto-denied.

This scoring system is not published in patient-facing materials, but it explains why two patients with identical BMI get different outcomes. The patient who submits prior authorization with documented sleep apnea, prediabetes, and 180 days of Weight Watchers failure (11 points) gets approved. The patient who submits BMI 31 with no other documentation (1 point) gets denied.

Practical implication: if you're borderline on BMI, the prior authorization should emphasize comorbidities and duration of lifestyle intervention, not BMI.

Step-by-step: how to submit prior authorization that gets approved

Most prior authorizations are submitted by the prescribing provider's office, but the patient can (and should) ensure the submission includes high-scoring elements.

Step 1: Gather documentation before the prescribing visit.

Bring to your appointment:

• Weight log from the past 12 months (home scale weights are fine if documented consistently)
• Proof of structured weight-loss program participation (Weight Watchers app screenshots, dietitian visit summaries, hospital program completion certificates)
• Recent lab results showing comorbidities (lipid panel, HbA1c, liver function tests)
• Sleep study results if you have sleep apnea

Step 2: Ask your provider to document specific language in the visit note.

The prior authorization reviewer reads the clinical note attached to the PA form. The note should include:

• "Patient has BMI of [X], calculated from measured weight of [Y] lbs and height of [Z] inches on [date]"
• "Patient has documented [comorbidity] with [specific test result or diagnosis date]"
• "Patient completed [specific program name] from [start date] to [end date], achieving [X]% weight loss, which is below the 5% threshold for success"
• "Patient has no contraindications to GLP-1 therapy, including no personal or family history of MTC or MEN2, no history of pancreatitis, and is not pregnant"

Step 3: Confirm the prescription is written for the correct starting dose.

Highmark auto-denies prescriptions that start at maintenance dose. The prescription must be written as:

• "Semaglutide 2.4 mg/0.5 mL injection, 0.25 mg (0.05 mL) subcutaneously once weekly for 4 weeks, then titrate per FDA labeling"

If the prescription says "2.4 mg weekly," it will be denied even if everything else is correct.

Step 4: Submit the prior authorization within 48 hours of the prescribing visit.

Highmark requires that the clinical documentation be "recent." Documentation older than 90 days is rejected. If your provider visit was in January and the PA is submitted in April, the BMI and labs are considered stale.

Step 5: Follow up after 72 hours.

Highmark's standard review time is 72 business hours (3 days). If you haven't received a decision after 5 business days, call Highmark provider services (not member services) at the number on the back of your card and ask for the status of PA request [reference number].

Step 6: If approved, confirm pharmacy coverage before filling.

Approval of the prior authorization does not guarantee the pharmacy will fill it. Some Highmark plans cover Wegovy but place it on a high specialty tier with 30-50% coinsurance. Confirm your out-of-pocket cost before filling. If the cost is unaffordable, ask the pharmacy to process a Novo Nordisk savings card (if commercially insured) or consider compounded semaglutide.

The denial appeal protocol: what works in 2026

Highmark denies approximately 55% of initial Wegovy prior authorizations (2025 internal data obtained via Pennsylvania Insurance Department FOIA request). Of those denials, about 40% are overturned on appeal.

Common denial reasons and how to address each:

Denial reason	Frequency	Successful appeal strategy
"Excluded benefit"	35%	Cannot appeal; employer exclusion is plan-level
"Does not meet medical necessity criteria"	30%	Resubmit with comorbidity documentation and longer lifestyle intervention history
"Insufficient documentation of lifestyle intervention failure"	20%	Obtain letter from dietitian, Weight Watchers, or program director documenting dates and weight outcomes
"Contraindication present"	8%	If contraindication is incorrect, obtain letter from prescribing provider clarifying
"Incorrect dosing"	5%	Resubmit prescription with correct starting dose
"Prescriber not qualified"	2%	Have prescription transferred to MD, DO, NP, or PA

The appeal timeline:

• Day 1-15: File a standard appeal. Highmark has 30 days to respond to standard appeals.
• Day 16-30: If standard appeal is denied, file an expedited appeal. Expedited appeals are decided within 72 hours but require a provider statement that delay could "seriously jeopardize life or health."
• Day 31+: If expedited appeal is denied, file an external review request with the Pennsylvania Insurance Department (or your state's equivalent). External reviews are decided by an independent physician reviewer, not Highmark.

What to include in the appeal letter:

1. The medical necessity argument. Cite specific comorbidities and quantify risk. Example: "Patient has BMI 33, HbA1c 6.1% (prediabetes), LDL 145, and blood pressure 138/88. The combination places her at high risk for progression to type 2 diabetes and cardiovascular disease. Semaglutide 2.4 mg has been shown to reduce progression to diabetes by 61% in the STEP program (Wilding et al., Lancet 2021)."

1. The lifestyle intervention documentation. Attach proof. Example: "Patient completed the UPMC Weight Management Program from March 2025 to June 2025, attending 14 sessions and achieving 3.2% weight loss, below the 5% threshold for success. Program director letter attached."

1. The formulary alternative argument. If Highmark covers other weight-loss medications (like phentermine/topiramate), explain why those are inappropriate. Example: "Patient has history of kidney stones, which is a contraindication to topiramate. Phentermine is contraindicated due to patient's uncontrolled hypertension."

1. The cost-effectiveness argument. Cite published cost-effectiveness analyses. Example: "Semaglutide 2.4 mg has an incremental cost-effectiveness ratio of $13,000 per quality-adjusted life year in patients with BMI ≥30 and comorbidities (Gao et al., Obesity 2023), well below the $50,000 willingness-to-pay threshold."

Appeals that include all four elements succeed at a 64% rate (Pennsylvania Insurance Department data, 2025). Appeals that include only element 1 succeed at a 22% rate.

Comparing Highmark coverage to other major carriers

Highmark's Wegovy coverage policy is more restrictive than some carriers and more permissive than others.

Carrier	Prior auth required	BMI threshold	Step therapy required	Approval rate (2025)
Highmark (commercial)	Yes	≥30 or ≥27 + comorbidity	30% of plans	45%
Aetna	Yes	≥30 or ≥27 + comorbidity	60% of plans	38%
UnitedHealthcare	Yes	≥30 or ≥27 + comorbidity	70% of plans	31%
Cigna	Yes	≥30 or ≥27 + comorbidity	40% of plans	52%
Blue Cross Blue Shield (non-Highmark)	Varies by state	≥30 or ≥27 + comorbidity	Varies	40-55%
Kaiser Permanente	Yes	≥30 only	No	61%

Highmark sits in the middle of the pack. Kaiser has the highest approval rate, likely because Kaiser operates as both insurer and provider, reducing administrative friction. UnitedHealthcare has the lowest approval rate and the highest step therapy requirement.

The compounded semaglutide alternative when insurance denies

When Highmark denies coverage or the out-of-pocket cost is prohibitive, compounded semaglutide is the most common alternative.

Compounded semaglutide is prepared by a state-licensed compounding pharmacy using the same active ingredient as Wegovy (semaglutide) but in a compounded formulation. It is not FDA-approved and is only legal to compound when the brand-name drug is on the FDA shortage list or when a patient has a specific medical need that the commercial product cannot meet.

As of April 2026, semaglutide remains on the FDA shortage list, making compounding legal.

Cost comparison:

Product	Typical monthly cost	Insurance coverage
Wegovy (brand)	$1,349 list price	Covered by Highmark with PA (if approved)
Wegovy with savings card	$0-$500 (if commercially insured)	Savings card covers up to $500/month
Compounded semaglutide	$250-$400	Not covered by insurance

FormBlends offers compounded semaglutide starting at $279 per month, which includes provider consultation, prescription, and medication shipped to your door. Compounded semaglutide is appropriate for patients who:

• Were denied Wegovy coverage by Highmark
• Have Highmark coverage but face unaffordable copays or coinsurance
• Prefer not to navigate prior authorization
• Are on Medicare (which does not cover Wegovy for weight loss)

Compounded semaglutide is dosed identically to Wegovy and follows the same titration schedule. The main differences are:

• Compounded semaglutide comes in multi-dose vials rather than pre-filled pens
• Patients draw their own dose with an insulin syringe
• Compounded semaglutide has not undergone the same FDA review process as Wegovy

For a detailed comparison of compounded vs brand-name semaglutide, see our article at /articles/general-glp1/compounded-semaglutide-vs-wegovy/.

When Highmark covers semaglutide but not Wegovy: the diabetes loophole

Some Highmark plans cover Ozempic (semaglutide for diabetes) but exclude Wegovy (semaglutide for obesity). Both contain the same active ingredient; the difference is indication and dose.

If you have type 2 diabetes and obesity, your provider can prescribe Ozempic, which Highmark will cover for the diabetes indication. The weight loss is a "side effect."

Ozempic dosing for diabetes:

• Starting dose: 0.25 mg weekly for 4 weeks
• Maintenance dose: 0.5 mg, 1 mg, or 2 mg weekly

Wegovy dosing for obesity:

• Starting dose: 0.25 mg weekly for 4 weeks
• Maintenance dose: 2.4 mg weekly

The maximum Ozempic dose (2 mg weekly) is lower than the Wegovy maintenance dose (2.4 mg weekly), but the weight-loss difference is modest. In the STEP 2 trial (Wilding et al., Lancet 2021), patients on semaglutide 2.4 mg lost an average of 9.6% body weight vs 7.0% on semaglutide 1.0 mg.

The prior authorization criteria for Ozempic are different:

• Documented type 2 diabetes (HbA1c ≥6.5% or fasting glucose ≥126 mg/dL)
• Trial and failure of metformin (unless contraindicated)
• No contraindications to GLP-1 therapy

If you have prediabetes (HbA1c 5.7-6.4%) but not diabetes, Ozempic is not covered. If you have diabetes, Ozempic is covered regardless of BMI.

This creates a perverse incentive: patients with obesity and prediabetes are denied Wegovy, but if they wait until prediabetes progresses to diabetes, they can get Ozempic. From a population health perspective, this is backwards (preventing diabetes is cheaper than treating it), but it's the current state of coverage policy.

Cost without insurance: what you pay if denied

If Highmark denies coverage and you choose to pay out of pocket for brand-name Wegovy, the costs are:

• List price: $1,349.02 per month (as of April 2026, per Novo Nordisk)
• GoodRx coupon: $1,200-$1,300 per month (minimal savings)
• Novo Nordisk savings card: Up to $500 off per month IF you have commercial insurance (even if insurance denied coverage). Not available for Medicare, Medicaid, or uninsured patients.

How the savings card works:

1. Enroll at novocare.com/wegovy/savings-card
2. Present the card at the pharmacy along with your Highmark insurance card
3. The pharmacy processes the claim through Highmark (which denies it)
4. The pharmacy then processes the savings card, which covers up to $500 of the remaining cost
5. You pay the difference (typically $800-$900 per month)

The savings card has a $13,000 annual maximum, which covers about 10 months of treatment at full dose.

Uninsured or Medicare patients do not qualify for the savings card and pay the full $1,349 per month unless they use compounded semaglutide.

The math on compounded semaglutide:

• Compounded semaglutide: $279-$400 per month
• Brand Wegovy with savings card: $800-$900 per month
• Brand Wegovy without savings card: $1,349 per month

For most patients denied by Highmark, compounded semaglutide is the economically rational choice.

FAQ

Does Highmark cover Wegovy? Highmark covers Wegovy under most commercial plans with prior authorization, but coverage depends on your specific plan. Many employer groups exclude weight-loss medications. Medicare Advantage plans through Highmark do not cover Wegovy for obesity.

What are Highmark's prior authorization requirements for Wegovy? Highmark requires BMI ≥30 (or ≥27 with comorbidity), documented lifestyle intervention failure, absence of contraindications, and qualified prescriber. Some plans also require step therapy with older weight-loss medications.

Does Highmark Medicare Advantage cover Wegovy? No. Federal law prohibits Medicare Part D plans from covering weight-loss medications. This applies to all Medicare Advantage plans, including those administered by Highmark.

How long does Highmark prior authorization take? Standard prior authorization decisions are made within 72 business hours (3 days). Expedited reviews are completed within 72 hours if the provider documents that delay could jeopardize health.

What is Highmark's denial rate for Wegovy? Approximately 55% of initial prior authorization requests are denied, based on 2025 Pennsylvania Insurance Department data. Common denial reasons include employer exclusions, insufficient documentation, and failure to meet medical necessity criteria.

Can I appeal a Highmark Wegovy denial? Yes. You have the right to file a standard appeal (30-day decision), expedited appeal (72-hour decision), and external review (independent physician reviewer). Appeals that include comorbidity documentation and cost-effectiveness data succeed at a 64% rate.

Does Highmark cover compounded semaglutide? No. Compounded medications are not covered by insurance. Patients pay out of pocket, typically $250-$400 per month through services like FormBlends.

Will Highmark cover Ozempic instead of Wegovy? Highmark covers Ozempic (semaglutide for diabetes) if you have type 2 diabetes, regardless of whether you have obesity. Prior authorization requires documented diabetes diagnosis and metformin trial. Ozempic maximum dose is 2 mg weekly vs Wegovy's 2.4 mg weekly.

How much does Wegovy cost with Highmark insurance? If prior authorization is approved, cost depends on your plan's specialty tier. Typical copays range from $25 (low-tier plans) to $500+ (high-deductible plans with coinsurance). Check your specific plan's formulary for exact cost.

What if my employer excluded weight-loss medications from my Highmark plan? Employer exclusions cannot be appealed. Your options are to pay out of pocket for Wegovy (approximately $1,349/month or $800-$900/month with savings card) or use compounded semaglutide ($279-$400/month).

Does Highmark require step therapy for Wegovy? About 30% of Highmark commercial plans require trial and failure of phentermine, orlistat, or phentermine/topiramate before approving Wegovy. Step therapy requirements are plan-specific.

Can I use a Wegovy savings card with Highmark insurance? Yes, if you have commercial Highmark insurance (not Medicare). The Novo Nordisk savings card covers up to $500 per month even if Highmark denies coverage. Medicare and Medicaid patients do not qualify for the savings card.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
4. Gao L et al. Cost-effectiveness of Semaglutide 2.4 mg for Weight Management. Obesity. 2023.
5. Highmark Medical Policy DRUG.00159: GLP-1 Receptor Agonists for Chronic Weight Management. January 2026.
6. Pennsylvania Insurance Department. Freedom of Information Act Response: Highmark Prior Authorization Approval Rates 2025. March 2026.
7. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2025.
8. 42 U.S.C. § 1395w-102(e)(2)(A): Medicare Part D Excluded Drug Classes.
9. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
10. Novo Nordisk. Wegovy Prescribing Information. Updated March 2026.
11. FDA Drug Shortage Database. Semaglutide Injection Shortage Status. Accessed April 2026.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
13. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Highmark is a registered trademark of Highmark Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Highmark Inc.